PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Julia Alejandra Pezuk,
Elvis Terci Valera,
María Sol Brassesco.
Over the years, polo-like kinase 1 (PLK1) has garnered great interest as
a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine
kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response
in eukaryotic cells. In this review, we summarize the functions of PLK1
during cell cycle progression, its roles in human pediatric cancer and its value as a
prognostic factor. Furthermore, we introduce the advances in pharmacological inhibition
and the newly chemotherapeutic development of small-molecules to target
PLK1 in cancer treatment. Finally, clinical trials with PLK1 inhibitors are briefly
Keywords: Chemotherapy, inhibitors, pediatric tumors, PLK1, radiotherapy, treatment.
Rights & PermissionsPrintExport